September 25, 2017 8:08 PM ET


Company Overview of ARCA biopharma, Inc.

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

11080 CirclePoint Road

Suite 140

Westminster, CO 80020

United States

20 Employees



Key Executives for ARCA biopharma, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 72
Total Annual Compensation: $294.0K
Chief Operating Officer
Age: 58
Total Annual Compensation: $292.9K
Senior Vice President, General Counsel and Secretary
Age: 58
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2016.

ARCA biopharma, Inc. Key Developments

ARCA biopharma Mulls Acquisitions

ARCA biopharma, Inc. (NasdaqCM:ABIO)intends to pursue acquisitions. ARCA has filed a Follow-on Equity Offering. The company intends to use the proceeds to invest in or acquire businesses or technologies that the company believes are complementary to it.

ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial

ARCA biopharma, Inc. announced the completion of enrollment for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential genetically-targeted treatment for atrial fibrillation (AF). ARCA expects to report top-line Phase 2B data late in the first quarter of 2018. Two-hundred sixty-seven patients were randomized into the trial, slightly exceeding the target enrollment of 250 patients. The trial enrolled patients from the United States, Canada and Europe.

ARCA Biopharma, Inc. Announces Completion of Pre-Specified Phase 2B Interim Analysis

ARCA biopharma, Inc. announced that the GENETIC-AF trial Data and Safety Monitoring Board (DSMB) completed its pre-specified Phase 2B interim analysis. Based on its efficacy and safety review, the DSMB recommended completion of the Phase 2B trial with no changes to the trial design. GENETIC-AF is a clinical trial evaluating Gencaro as a potential treatment for a trial fibrillation. The Gencaro development program has been granted Fast Track designation by the U.S. Food and Drug Administration. GENETIC-AF is a Phase 2B, adaptive design, multi-center, randomized, double-blind, superiority clinical trial comparing the safety and efficacy of Gencaro to TOPROL-XL for the treatment and prevention of recurrent a trial fibrillation or flutter in heart failure patients with reduced left ventricular ejection fraction.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ARCA biopharma, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at